Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

ATRA

Atara Biotherapeutics Inc

Jun 14 • 04:00PM ET

0.5110

Dollar change -0.0165
Percentage change -3.13	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWN SCHA VTWO VHT IWC FESM VTWV

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.12	Insider Own	18.18%	Shs Outstand	106.45M	Perf Week	-3.37%
Market Cap	61.53M	Forward P/E	-	EPS next Y	-0.58	Insider Trans	-1.18%	Shs Float	98.52M	Perf Month	-20.16%
Income	-233.11M	PEG	-	EPS next Q	-0.09	Inst Own	66.10%	Short Float	11.44%	Perf Quarter	-17.69%
Sales	34.70M	P/S	1.77	EPS this Y	75.33%	Inst Trans	-0.29%	Short Ratio	9.33	Perf Half Y	-24.63%
Book/sh	-0.82	P/B	-	EPS next Y	9.94%	ROA	-99.76%	Short Interest	11.27M	Perf Year	-75.55%
Cash/sh	0.39	P/C	1.33	EPS next 5Y	-	ROE	-2014.86%	52W Range	0.20 - 2.54	Perf YTD	-0.35%
Dividend Est.	2.00 (391.39%)	P/FCF	-	EPS past 5Y	13.12%	ROI	-	52W High	-79.84%	Beta	0.56
Dividend TTM	-	Quick Ratio	0.50	Sales past 5Y	25.21%	Gross Margin	57.34%	52W Low	157.30%	ATR (14)	0.06
Dividend Ex-Date	-	Current Ratio	0.59	EPS Y/Y TTM	-1.74%	Oper. Margin	-636.24%	RSI (14)	37.28	Volatility	10.02% 9.85%
Employees	225	Debt/Eq	-	Sales Y/Y TTM	-39.63%	Profit Margin	-671.70%	Recom	2.67	Target Price	4.17
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	68.60%	Payout	-	Rel Volume	1.06	Prev Close	0.53
Sales Surprise	10.80%	EPS Surprise	10.40%	Sales Q/Q	2131.40%	Earnings	May 09 AMC	Avg Volume	1.21M	Price	0.51
SMA20	-13.91%	SMA50	-20.40%	SMA200	-40.74%	Trades		Volume	1,279,838	Change	-3.13%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-09-23	Downgrade	Mizuho	Buy → Neutral	$31 → $1
Nov-09-23	Downgrade	H.C. Wainwright	Buy → Neutral
Nov-09-23	Downgrade	Evercore ISI	Outperform → In-line
Jul-20-22	Downgrade	Citigroup	Neutral → Sell	$8 → $3
Jul-13-22	Downgrade	Stifel	Buy → Hold	$16 → $5
Jul-13-22	Downgrade	JP Morgan	Overweight → Neutral	$10
May-10-22	Downgrade	Citigroup	Buy → Neutral	$15 → $8
May-13-21	Upgrade	JP Morgan	Neutral → Overweight	$23 → $29
Dec-09-20	Downgrade	Citigroup	Buy → Neutral	$20 → $27
Dec-08-20	Reiterated	H.C. Wainwright	Buy	$28 → $31
Nov-10-20	Reiterated	H.C. Wainwright	Buy	$26 → $28
Jun-30-20	Initiated	Evercore ISI	Outperform
Jun-15-20	Initiated	H.C. Wainwright	Buy	$25
Apr-23-20	Upgrade	Citigroup	Neutral → Buy	$14
Nov-08-19	Downgrade	JP Morgan	Overweight → Neutral	$43 → $22
Sep-27-19	Downgrade	Goldman	Neutral → Sell	$14 → $9
Sep-16-19	Downgrade	Jefferies	Buy → Hold	$32 → $15
Jun-04-19	Upgrade	Citigroup	Sell → Neutral	$23 → $24
May-30-19	Initiated	ROTH Capital	Buy
May-23-19	Initiated	Stifel	Buy

Show Previous Ratings

Jun-12-24 07:00AM	Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now (GlobeNewswire)
Jun-11-24 07:00AM	Presenting on the Emerging Growth Conference 72 Day 1 on June 12 Register Now (GlobeNewswire) +7.68%
Jun-07-24 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -7.08%
Jun-05-24 04:01PM	Atara Biotherapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (Business Wire)
May-29-24 04:01PM	Atara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual Meeting (Business Wire) -8.42%
11:57AM	Loading…
May-20-24 11:57AM	Atara Biotherapeutics Files Biologics License Application for Tabelecleucel with FDA; Shares Rise (MT Newswires) +16.39%
09:25AM	Atara Biotherapeutics Submits Tabelecleucel (Tab-cel) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA (Business Wire)
May-09-24 10:57PM	ATRA Stock Earnings: Atara Biotherapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:15PM	Atara Biotherapeutics (ATRA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:17PM	Atara Biotherapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress (Business Wire)
May-03-24 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-05-24 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-28-24 01:53PM	ATRA Stock Earnings: Atara Biotherapeutics Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace)
09:40AM	Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:40AM	Loading…
08:40AM	Atara Biotherapeutics: Q4 Earnings Snapshot (Associated Press Finance)
08:30AM	Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress (Business Wire)
Feb-29-24 09:05AM	Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy (Business Wire)
Feb-28-24 04:30PM	Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care Conference (Business Wire)
Feb-14-24 09:00AM	Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis (Business Wire)
Jan-31-24 06:30PM	Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel Data in The Lancet Oncology (Business Wire)
Jan-11-24 01:26AM	Seth Klarman's Firm Exits Atara Biotherapeutics Inc Holding (GuruFocus.com) +5.31%
01:26AM	Seth Klarman's Exit from Atara Biotherapeutics Inc (GuruFocus.com)
Jan-08-24 09:00AM	Atara Biotherapeutics Announces $15 Million Registered Direct Offering (Business Wire) +25.28%
08:00AM	Atara Biotherapeutics to Present Recent Progress and Key Upcoming Milestones at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Jan-04-24 04:01PM	Atara Biotherapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-20-23 04:01PM	Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel Partnership with Pierre Fabre Laboratories (Business Wire)
Dec-11-23 12:00PM	Atara Biotherapeutics Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting (Business Wire)
Dec-01-23 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-29-23 06:05PM	Atara Biotherapeutics To Present Positive New Tab-cel Clinical Data During Oral Session at ESMO Immuno-Oncology Annual Congress 2023 (Business Wire) +13.36%
12:29PM	Loading…
Nov-24-23 12:29PM	Atara Biotherapeutics (ATRA) Slumps 57% in a Month: Here's Why (Zacks) +13.93%
Nov-22-23 04:01PM	Atara Biotherapeutics to Participate at the 6th Annual Evercore ISI HealthCONx Conference (Business Wire) +13.22%
09:14AM	Billionaire Seth Klarmans Biotech Stock Picks (Insider Monkey)
Nov-10-23 04:01PM	Atara Biotherapeutics To Participate at the Stifel Healthcare Conference (Business Wire)
Nov-09-23 08:23AM	Why Is Atara Biotherapeutics (ATRA) Stock Down 50% Today? (InvestorPlace) -80.17%
06:40AM	Ataras cell therapy approach to MS falls short in study (BioPharma Dive)
Nov-08-23 05:35PM	Atara Biotherapeutics Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple Sclerosis (Business Wire) -9.02%
Nov-05-23 12:50PM	Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-02-23 05:42AM	Atara Biotherapeutics Inc (ATRA) Announces Q3 2023 Financial Results and Expanded Global Partnership (GuruFocus.com) -5.56%
02:25AM	Q3 2023 Atara Biotherapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-01-23 08:35AM	Atara Biotherapeutics: Q3 Earnings Snapshot (Associated Press Finance)
08:30AM	Atara Biotherapeutics Announces Expanded Global Tab-cel Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial Results (Business Wire)
Oct-06-23 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-21-23 09:19AM	Atara (ATRA) Up 11% on Regulatory Update From Blood Cancer Study (Zacks)
Sep-19-23 04:01PM	Atara Biotherapeutics Announces Plans to Submit Tab-cel® BLA in Q2 2024 Following FDA Agreement on Comparability (Business Wire)
Sep-01-23 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.16%
Aug-31-23 04:01PM	Atara Biotherapeutics to Participate in Cell Therapies in Autoimmune Panel Discussion at the Citi 18th Annual BioPharma Conference (Business Wire)
Aug-13-23 10:44AM	10 Most Promising Penny Stocks According to Analysts (Insider Monkey)
Aug-08-23 05:30PM	Atara Biotherapeutics (ATRA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:18PM	Atara Biotherapeutics: Q2 Earnings Snapshot (AP Finance)
04:01PM	Atara Biotherapeutics Announces Second Quarter 2023 Financial Results and Operational Progress (Business Wire)
Aug-04-23 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-01-23 04:01PM	Atara Biotherapeutics to Announce Second Quarter 2023 Financial Results on Tuesday, August 8, 2023 (Business Wire)
Jul-31-23 04:01PM	Atara Biotherapeutics to Participate in the Canaccord Genuity 43rd Annual Growth Conference (Business Wire) +7.28%
Jul-29-23 11:07AM	10 Stocks That Will Go Up 1000 Percent (Insider Monkey)
Jul-17-23 07:29AM	3 Doomed Biotech Stocks Destined for Disaster (InvestorPlace) +6.56%
Jul-07-23 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +11.45%
Jun-16-23 06:05AM	Time To Worry? Analysts Just Downgraded Their Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Outlook (Simply Wall St.) -6.07%
Jun-07-23 04:01PM	Atara Biotherapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference (Business Wire)
Jun-05-23 09:00AM	Atara Biotherapeutics Presents Updated Tab-cel® Clinical Effectiveness Data at ASCO 2023 (Business Wire)
Jun-02-23 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-18-23 07:09AM	Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Analysts Are More Bearish Than They Used To Be (Simply Wall St.)
May-08-23 05:15PM	Atara Biotherapeutics (ATRA) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:12PM	Atara Biotherapeutics: Q1 Earnings Snapshot (AP Finance)
04:01PM	Atara Biotherapeutics Announces First Quarter 2023 Financial Results and Operational Progress (Business Wire)
May-07-23 08:59AM	The Market Doesn't Like What It Sees From Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Revenues Yet (Simply Wall St.)
May-05-23 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.82%
May-01-23 04:01PM	Atara Biotherapeutics to Announce First Quarter 2023 Financial Results on Monday, May 8, 2023 (Business Wire)
Apr-16-23 12:08PM	3 Stocks to Buy That Could Be the Next Biotech Breakthrough (InvestorPlace)
Mar-31-23 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-24-23 09:35AM	Atara Biotherapeutics (ATRA) Loses -33.02% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Mar-03-23 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
09:40AM	Are Medical Stocks Lagging Apexigen, Inc. (APGN) This Year? (Zacks)
Mar-01-23 04:01PM	Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 43rd Annual Health Care Conference (Business Wire)
Feb-21-23 04:01PM	Atara Biotherapeutics to Participate in the H.C. Wainwright Cell Therapy Virtual Conference (Business Wire) -9.96%
Feb-15-23 06:58AM	The past five years for Atara Biotherapeutics (NASDAQ:ATRA) investors has not been profitable (Simply Wall St.)
Feb-08-23 05:15PM	Atara Biotherapeutics (ATRA) Reports Q4 Loss, Misses Revenue Estimates (Zacks) -7.69%
04:01PM	Atara Biotherapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Operational Progress (Business Wire)
06:00AM	Pierre Fabre to Commercialize and Distribute the First Approved Allogeneic T-cell Immunotherapy in Europe Following Transfer of the European Commission Marketing Authorization of EBVALLO (tabelecleucel) (Business Wire)
Feb-06-23 08:00AM	Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on Wednesday, February 8, 2023 (Business Wire)
Feb-03-23 04:01PM	Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.31%
Jan-13-23 04:01PM	Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-04-23 04:01PM	Atara Biotherapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-24-22 10:07AM	3 Under-the-Radar Biotech Stocks to Buy in 2022 (Motley Fool)
Dec-20-22 04:33PM	Atara Biotherapeutics Announces $31 Million Royalty Interest Financing Agreement with HealthCare Royalty (Business Wire)
Dec-19-22 08:00AM	Atara Biotherapeutics Announces Changes to Its Board of Directors (Business Wire)
07:00AM	Atara Biotherapeutics Ebvallo (tabelecleucel) Receives European Commission Approval as First Ever Therapy for Adults and Children with EBV+ PTLD (Business Wire)
Dec-15-22 04:01PM	Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -10.82%
Dec-12-22 10:00AM	Atara Biotherapeutics Presents Updated Clinical Data from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 64th American Society of Hematology (ASH) Annual Meeting (Business Wire)
Dec-02-22 04:01PM	Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +8.18%
Nov-23-22 08:00AM	Atara Biotherapeutics to Participate at the Evercore ISI 5th Annual HealthCONx Conference (Business Wire)
Nov-22-22 05:03AM	Newsflash: Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Analysts Have Been Trimming Their Revenue Forecasts (Simply Wall St.)
Nov-10-22 05:52AM	Atara Biotherapeutics Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS In Line (Simply Wall St.) +23.97%
Nov-09-22 04:01PM	Atara Biotherapeutics to Participate at the Stifel Healthcare Conference (Business Wire) -20.82%
Nov-08-22 05:15PM	Atara Biotherapeutics (ATRA) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Atara Biotherapeutics Announces Third Quarter 2022 Financial Results and Operational Progress (Business Wire)
Nov-04-22 04:01PM	Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-01-22 04:05PM	Atara Biotherapeutics to Announce Third Quarter 2022 Financial Results on Tuesday, November 8, 2022 (Business Wire)
Oct-26-22 02:01AM	Atara Biotherapeutics Presents New MRI and Updated Open-Label Extension Data from Phase 1 Study of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2022 (Business Wire)
Oct-14-22 07:08AM	CHMP Recommends Approval of Atara Biotherapeutics Ebvallo (tabelecleucel) for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (Business Wire) -6.52%

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Touchon Pascal	President and CEO	May 16 '24	Sale	0.62	81,506	50,289	1,829,146	May 20 08:34 PM
Nguyen AnhCo	EVP, Chief Sci. & Tech Officer	May 16 '24	Sale	0.62	42,899	26,469	898,498	May 20 08:34 PM
Murugan Amar	EVP, Chief Legal Officer	May 16 '24	Sale	0.62	32,401	19,991	695,120	May 20 08:33 PM
Hyllengren Eric J	EVP, CFO	May 16 '24	Sale	0.62	28,648	17,676	645,671	May 20 08:33 PM
Henrich Jill	EVP, Global Head RA & Quality	May 16 '24	Sale	0.62	25,750	15,888	529,251	May 20 08:32 PM
Touchon Pascal	President and CEO	Mar 04 '24	Sale	0.72	24,844	17,888	1,910,652	Mar 06 06:19 PM
Nguyen AnhCo	EVP, Chief Sci. & Tech Officer	Mar 04 '24	Sale	0.72	10,746	7,737	941,397	Mar 06 06:18 PM
Murugan Amar	EVP, Chief Legal Officer	Mar 04 '24	Sale	0.72	10,044	7,232	727,521	Mar 06 06:18 PM
Henrich Jill	EVP, Global Head RA & Quality	Mar 04 '24	Sale	0.72	3,879	2,793	555,001	Mar 06 06:16 PM
Touchon Pascal	President and CEO	Nov 16 '23	Sale	0.39	20,409	7,939	655,496	Nov 20 05:31 PM
Joshi Manher	EVP, Chief Medical Officer	Nov 16 '23	Sale	0.39	12,287	4,780	171,284	Nov 20 05:30 PM
Hyllengren Eric J	SVP, CFO	Nov 16 '23	Sale	0.39	11,958	4,652	205,998	Nov 20 05:29 PM
Nguyen AnhCo	EVP, Chief Sci. & Tech Officer	Nov 16 '23	Sale	0.39	8,856	3,445	277,143	Nov 20 05:31 PM
Murugan Amar	EVP, Chief Legal Officer	Nov 16 '23	Sale	0.39	8,307	3,231	257,084	Nov 20 05:30 PM
Henrich Jill	EVP, Global Head RA & Quality	Nov 16 '23	Sale	0.39	3,267	1,271	104,424	Nov 20 05:29 PM
Gallagher Carol Giltner	Director	Nov 14 '23	Buy	0.31	90,980	28,186	459,418	Nov 15 05:07 PM
Gallagher Carol Giltner	Director	Nov 13 '23	Buy	0.22	179,020	40,029	368,438	Nov 15 05:07 PM
DOBMEIER ERIC	Director	Nov 10 '23	Buy	0.23	446,825	101,340	563,325	Nov 14 06:27 PM
HEIDEN WILLIAM K	Director	Nov 10 '23	Buy	0.25	100,000	25,330	209,000	Nov 14 06:29 PM
Touchon Pascal	President and CEO	Aug 16 '23	Sale	1.65	30,766	50,835	675,905	Aug 18 06:25 PM
Nguyen AnhCo	EVP, Chief Sci. & Tech Officer	Aug 16 '23	Sale	1.65	15,126	24,997	285,999	Aug 18 06:25 PM
Murugan Amar	EVP, Chief Legal Officer	Aug 16 '23	Sale	1.65	8,672	14,330	265,391	Aug 18 06:25 PM
Hyllengren Eric J	SVP, CFO	Aug 16 '23	Sale	1.65	8,186	13,527	217,956	Aug 18 06:25 PM
Joshi Manher	EVP, Chief Medical Officer	Aug 16 '23	Sale	1.65	6,975	11,526	183,571	Aug 18 06:25 PM
Henrich Jill	EVP, Global Head RA & Quality	Aug 16 '23	Sale	1.65	3,346	5,531	107,691	Aug 18 06:25 PM
Touchon Pascal	President and CEO	Jun 27 '23	Sale	1.66	14,291	23,723	706,671	Jun 29 04:15 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ATRA

Atara Biotherapeutics Inc

Upgrade your FINVIZ experience